ELITE PHARMACEUTICALS INC /DE/
Form 3
January 06, 2003

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response	0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 3

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print of Type Responses)

1. Name and Address of Reporting Person*

Moore	John	A
(Last)	(First)	(Middle)

c/o Edson Moore Corp.
1011 Brookmeadow Road

(Street)

Wilmington	Delaware	19807
(City)	(State)	(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)

12/12/2002

3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)

4. Issuer Name and Ticker or Trading Symbol

Elite Pharmaceuticals, Inc. - AMEX: ELI

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

|X| Director |_| 10% Owner
|_| Officer (give title below) |_| Other (specify below)

6. If Amendment, Date of Original (Month/Day/Year)

7. Individual or Joint/Group Filing (Check Applicable line)

|X| Form filed by One Reporting Person

|_| Form filed by More than One Reporting Person

Table I -- Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature (Instr.
Common Stock, par value $0.01 per share ("Common Stock")	764,218	I	By Eds corpor

FORM 3 (continued)

Table II -- Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

3. Title and Amount of Securities Underlying Derivative Security

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exer-cisable	Expira-tion Date	(Instr. 4) Title	Amount or Number of Shares	4. Conve sion Exerc Price Deriv Secur
Warrant to purchase up to 100,000 shares of Common Stock	10-17-2000	10-17-2005	Common Stock	100,000	$18.00

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Explanation of Responses:

/s/ John A. Moore 12-16-2002

**Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.